Mark Avigan

5.3k citations

71 papers · 3.5k indexed · 1 hit paper · h-index 28

Impact in

Pharmacology top 0.2%
- Drug-Induced Hepatotoxicity and Protection
- Pharmacogenetics and Drug Metabolism
Hepatology top 1%
- Liver Diseases and Immunity

Papers in ⓘ

Epidemiology 24
- Liver Disease Diagnosis and Treatment 22
Pharmacology 23
- Drug-Induced Hepatotoxicity and Protection 20
- Pharmacogenetics and Drug Metabolism 9

Co-authors: David Levens (5 shared papers)Ann Corken Mackey (2 shared papers)Lanh Green (2 shared papers)Patricia A. Dinndorf (1 shared paper)Henry C. Krutzsch (2 shared papers)Takeshi Tomonaga (2 shared papers)Leonard S. Bazar (4 shared papers)Raúl J. Andrade (4 shared papers)
Journals: Drug Safety (11 papers)Alimentary Pharmacology & Therapeutics (4 papers)Hepatology (4 papers)Journal of Biological Chemistry (3 papers)Clinical Pharmacology & Therapeutics (3 papers)
Partner nations: United States United Kingdom Spain

In The Last Decade

Mark Avigan

70 papers receiving 3.3k citations

Hit Papers

align trajectories log scale

Case Definition and Phenotype Standardization in Drug-Induced Liver Injury 2011 · 713 citations

Peers

Countries citing papers authored by Mark Avigan

Since Specialization

Citations

This map shows the geographic impact of Mark Avigan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Avigan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Avigan more than expected).

Fields of papers citing papers by Mark Avigan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Avigan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Avigan. The network helps show where Mark Avigan may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Avigan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Avigan Line = papers co-authored together Mark Avigan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 71 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Case Definition and Phenotype Standardization in Drug-Induced Liver Injury Clinical Pharmacology & Therapeutics ·Guruprasad P. Aithal, PB Watkins, Raúl J. Andrade, Dominique Larrey, Mariam Molokhia, Hajime Takikawa, CM Hunt, R.A. Wilke, Mark Avigan, Neil Kaplowitz, Einar S. Björnsson, Ann K. Daly Hit paper breakdown →	2011	713
2	Hepatosplenic T Cell Lymphoma Associated With Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease Journal of Pediatric Gastroenterology and Nutrition ·Ann Corken Mackey, Lanh Green, Li‐ching Liang, Patricia A. Dinndorf, Mark Avigan	2007	371
3	A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes & Development ·Robert Duncan, Leonard S. Bazar, Gregory Michelotti, Takeshi Tomonaga, Henry C. Krutzsch, Mark Avigan, David Levens	1994	287
4	Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, in vitro. Journal of Biological Chemistry ·Masato Takimoto, Takeshi Tomonaga, Michael J. Matunis, Mark Avigan, Henry C. Krutzsch, Gideon Dreyfuss, David Levens	1993	203
5	Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents Liver International ·Daniel L. Suzman, Lorraine Pelosof, Amy S. Rosenberg, Mark Avigan	2018	158
6	A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. Journal of Biological Chemistry ·Mark Avigan, Benjamin J. Strober, David Levens	1990	122
7	Randomized trial of chlorambucil for primary biliary cirrhosis Gastroenterology ·Jay H. Hoofnagle, Gary L. Davis, Daniel F. Schafer, Marion G. Peters, Mark Avigan, S. Chris Pappas, Reginald G. Hanson, Gerald Y. Minuk, Geoffrey Dusheiko, Gregory Campbell, R N MacSween, E. Anthony Jones	1986	107
8	Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients Journal of the American Academy of Dermatology ·Namita Kothary, Ida-Lina Diak, Allen Brinker, Shewit Bezabeh, Mark Avigan, Gerald J. Dal Pan	2011	95
9	Delivery of c-myc Antisense Phosphorothioate Oligodeoxynucleotides to Hematopoietic Cells in Culture by Liposome Fusion: Specific Reduction in c-myc Protein Expression Correlates with Inhibition of Cell Growth and DNA Synthesis Current topics in microbiology and immunology ·S.L. Loke, C.A. Stein, X. Zhang, Mark Avigan, Jack S. Cohen, Len Neckers	1988	88
10	Using controlled clinical trials to learn more about acute drug-induced liver injury Hepatology ·Paul B. Watkins, Paul J. Seligman, John Pears, Mark Avigan, John Senior	2008	84
11	Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States International Journal of Molecular Sciences ·Mark Avigan, Robert P. Mozersky, Leonard B. Seeff	2016	76
12	Telithromycin‐associated hepatotoxicity Hepatology ·Allen Brinker, Ronald T. Wassel, Jenna Lyndly, José Serrano, Mark Avigan, William M. Lee, Leonard B. Seeff	2008	74
13	Studies on the compartmentation of lipid in adipose cells. II. Cholesterol accumulation and distribution in adipose tissue components Journal of Lipid Research ·J. Farkas, A. Ángel, Mark Avigan	1973	70
14	Targeted Melting and Binding of a DNA Regulatory Element by a Transactivator of c-myc Journal of Biological Chemistry ·Leonard S. Bazar, Deborah L. Meighen, Violaine Harris, Robert Duncan, David Levens, Mark Avigan	1995	64
15	Brief Communication: Characteristics of Spontaneous Cases of Tuberculosis Associated with Infliximab Annals of Internal Medicine ·Angela Raval, Gita Akhavan-Toyserkani, Allen Brinker, Mark Avigan	2007	60
16	Clinically significant liver injury in patients treated with natalizumab Alimentary Pharmacology & Therapeutics ·Shewit Bezabeh, Crystal Flowers, Cindy Kortepeter, Mark Avigan	2010	56
17	An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system Pharmacoepidemiology and Drug Safety ·Eric Colman, Ana Szarfman, Jo Wyeth, Andrew D. Mosholder, Devanand Jillapalli, Jonathan G. Levine, Mark Avigan	2008	41
18	Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors Pharmacoepidemiology and Drug Safety ·Christopher G. Rowan, Allen Brinker, Parivash Nourjah, Jennie Chang, Andrew D. Mosholder, Jeffrey S. Barrett, Mark Avigan	2009	41
19	Treatment of chronic delta hepatitis with recombinant human alpha interferon. PubMed ·Jay H. Hoofnagle, Kevin D. Mullen, Matthew Peters, Mark Avigan, Yikyung Park, Jason R. Waggoner, J. L. Gerin, B. Hoyer, A. Smedile	1987	38
20	GATA-6 stimulates a cell line-specific activation element in the human lactase promoter American Journal of Physiology-Gastrointestinal and Liver Physiology ·Kevin Fitzgerald, Leonard S. Bazar, Mark Avigan	1998	38

About Mark Avigan

Mark Avigan is a scholar working on Epidemiology, Pharmacology, Hepatology, Molecular Biology and Surgery, having authored 71 papers that have together received 3.5k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (22 papers), Drug-Induced Hepatotoxicity and Protection (20 papers), Pharmacogenetics and Drug Metabolism (9 papers), Liver Diseases and Immunity (7 papers), Hepatitis C virus research (7 papers), Pharmacovigilance and Adverse Drug Reactions (4 papers), Liver physiology and pathology (4 papers) and Adipose Tissue and Metabolism (4 papers). The work is most often cited by research in Pharmacology (938 citations), Hepatology (562 citations), Toxicology (110 citations), Epidemiology (969 citations) and Oncology (620 citations). Mark Avigan has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include David Levens, Ann Corken Mackey, Lanh Green, Patricia A. Dinndorf, Henry C. Krutzsch, Takeshi Tomonaga, Leonard S. Bazar, Raúl J. Andrade, Neil Kaplowitz and Einar S. Björnsson. Their work appears in journals such as Drug Safety, Alimentary Pharmacology & Therapeutics, Hepatology, Journal of Biological Chemistry and Clinical Pharmacology & Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact